Autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients has often been capped at 65 years of age. However, Mohamad Mohty, MD, PhD, of the University Pierre & Marie Curie, Paris, France, explains why limiting ASCTs to those younger than 65 is a mistake, and outlines what guidelines would be more applicable when screening for patients eligible for transplants. Speaking from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. Prof. Mohty emphasizes that when suitable patients >65 years old do receive stem cell transplants, the results are often very positive, further encouraging the age cap of 65 years to be lifted.
Redundancy of age restrictions for MM treatment
